iBio, Inc. (IBIO) Receives U.S. Patent for iBioLaunch Platform that Causes Non-transgenic Plants to Rapidly Produce Proteins
iBio, Inc., a leader in the plant-made pharmaceutical field, today announced that the U.S. Patent and Trademark Office has issued a patent that covers the viral vectors comprising the iBioLaunch™ platform. iBio owns this proprietary technology that was developed by scientists at iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer). The iBioLaunch™ platform is a highly flexible technology that easily, cheaply and reliably causes non-tangenic plants to rapidly produce a large amount of recombinant protein in the plant biomass for biotherapeutics and vaccines. This whole plant approach allows for lower operating and capital expenses versus protein production…